Immutep Limited Investors Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: Globenewswire
- Class Action Initiation: The Portnoy Law Firm has advised Immutep investors of a class action for those who purchased securities between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: Immutep's TACTI-004 Phase III trial evaluated eftilagimod alfa in advanced lung cancer patients, but the lawsuit alleges that the company concealed the true status and prospects of the trial, leading to significant investor losses.
- Stock Price Plunge: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to futility, resulting in an over 82% drop in Immutep's ADR price, severely impacting investor confidence and asset value.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to reach out to discuss legal options for recovering losses, demonstrating the firm's commitment to supporting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.448
Low
12.00
Averages
12.00
High
12.00
Current: 0.448
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices by the company and certain officers, which could expose Immutep to significant legal risks.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the TACTI-004 Phase III trial would be discontinued due to futility, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44% to close at $0.48, indicating extreme market pessimism regarding the company's future.
- Trial Termination Impact: The Independent Data Monitoring Committee (IDMC) recommended halting the TACTI-004 trial based on safety and efficacy data, which represents a major setback for Immutep's research in non-small cell lung cancer treatment and could hinder future financing and partnership opportunities.
- Potential Legal Consequences: Investors are advised that they have until July 6, 2026, to apply as Lead Plaintiff in the class action, highlighting the potential for legal actions to have far-reaching effects on the company's reputation and financial health.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026.
- False Statements Allegation: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Investors suffered damages when the truth about Immutep was revealed, indicating that the company's public statements were false and materially misleading throughout the class period, which significantly impacted investor decisions and trust.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to seek free consultations to discuss their rights before the class action is certified, ensuring they can participate in claims to recover their losses.
See More
Immutep Faces Securities Fraud Class Action Lawsuit
- Class Action Notice: Bernstein Liebhard LLP reminds investors of Immutep Limited that the deadline to join the securities fraud class action lawsuit against the company is July 6, 2026, requiring investors to file necessary documents by this date to participate in the litigation.
- Lawsuit Background: The lawsuit targets investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, alleging that the company and certain senior officers made materially false and misleading statements regarding business operations, growth prospects, and financial stability, resulting in artificially inflated ADR prices.
- Investor Losses: The disclosure of these false statements allegedly led to significant losses for investors during the class period, highlighting major deficiencies in the company's transparency and compliance, which could impact future investor confidence.
- Legal Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which lowers the barrier for investor participation in the lawsuit and encourages more affected shareholders to join the class action for potential recovery.
See More
Reminder for Shareholder Class Action Lawsuits
- Lawsuit Overview: Holzer & Holzer LLC reminds investors of a class action lawsuit against Graphic Packaging Holding Company, alleging that from February 2025 to February 2026, the company failed to disclose critical inventory management information, potentially leading to investor losses.
- Deadline for Action: Investors must apply to be appointed lead plaintiff by July 6, 2026, to protect their legal rights, as failing to do so may result in the loss of their claims.
- Immutep Lawsuit: A similar class action against Immutep Limited alleges that from March 2025 to March 2026, the company did not disclose important information regarding the status and prospects of its TACTI-004 trial, with the same deadline for investors to act.
- Phreesia Lawsuit: The class action against Phreesia, Inc. involves misleading statements about its long-term growth outlook made between May 2025 and March 2026, with a deadline for lead plaintiff applications set for July 13, 2026.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep Limited, alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, highlighting serious governance concerns.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in an 82.44% drop in stock price, indicating significant risks in its research pipeline.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) fell by $2.27 to close at $0.48, reflecting market pessimism regarding the company's future prospects.
- Potential Legal Ramifications: The class action lawsuit could expose Immutep to substantial damages, further impacting its financial health and market credibility, potentially hindering future financing and business development.
See More
Immutep Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has advised Immutep investors of a class action for those who purchased securities between March 24, 2025, and March 12, 2026, with a deadline for lead plaintiff motions set for July 6, 2026, highlighting the urgency of legal action.
- Allegations: The lawsuit claims that Immutep concealed the true status of the TACTI-004 trial regarding the efficacy of efti, despite positive results in other trials, which misled investors and affected their investment decisions.
- Stock Price Plunge: Following the announcement on March 13, 2026, by the Independent Data Monitoring Committee to discontinue the TACTI-004 trial, Immutep's ADRs fell over 82%, reflecting a severe loss of market confidence and investor sentiment.
- Legal Support Offered: The Portnoy Law Firm is providing complimentary case evaluations to assist investors in recovering losses due to corporate misconduct, demonstrating their commitment to protecting investor rights and interests.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices by the company and certain officers, which could expose Immutep to significant legal risks.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the TACTI-004 Phase III trial would be discontinued due to futility, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44% to close at $0.48, indicating extreme market pessimism regarding the company's future.
- Trial Termination Impact: The Independent Data Monitoring Committee (IDMC) recommended halting the TACTI-004 trial based on safety and efficacy data, which represents a major setback for Immutep's research in non-small cell lung cancer treatment and could hinder future financing and partnership opportunities.
- Potential Legal Consequences: Investors are advised that they have until July 6, 2026, to apply as Lead Plaintiff in the class action, highlighting the potential for legal actions to have far-reaching effects on the company's reputation and financial health.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026.
- False Statements Allegation: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company falsely claimed in a Form-K filed on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Investors suffered damages when the truth about Immutep was revealed, indicating that the company's public statements were false and materially misleading throughout the class period, which significantly impacted investor decisions and trust.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to seek free consultations to discuss their rights before the class action is certified, ensuring they can participate in claims to recover their losses.
See More
Immutep Faces Securities Fraud Class Action Lawsuit
- Class Action Notice: Bernstein Liebhard LLP reminds investors of Immutep Limited that the deadline to join the securities fraud class action lawsuit against the company is July 6, 2026, requiring investors to file necessary documents by this date to participate in the litigation.
- Lawsuit Background: The lawsuit targets investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, alleging that the company and certain senior officers made materially false and misleading statements regarding business operations, growth prospects, and financial stability, resulting in artificially inflated ADR prices.
- Investor Losses: The disclosure of these false statements allegedly led to significant losses for investors during the class period, highlighting major deficiencies in the company's transparency and compliance, which could impact future investor confidence.
- Legal Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which lowers the barrier for investor participation in the lawsuit and encourages more affected shareholders to join the class action for potential recovery.
See More
Reminder for Shareholder Class Action Lawsuits
- Lawsuit Overview: Holzer & Holzer LLC reminds investors of a class action lawsuit against Graphic Packaging Holding Company, alleging that from February 2025 to February 2026, the company failed to disclose critical inventory management information, potentially leading to investor losses.
- Deadline for Action: Investors must apply to be appointed lead plaintiff by July 6, 2026, to protect their legal rights, as failing to do so may result in the loss of their claims.
- Immutep Lawsuit: A similar class action against Immutep Limited alleges that from March 2025 to March 2026, the company did not disclose important information regarding the status and prospects of its TACTI-004 trial, with the same deadline for investors to act.
- Phreesia Lawsuit: The class action against Phreesia, Inc. involves misleading statements about its long-term growth outlook made between May 2025 and March 2026, with a deadline for lead plaintiff applications set for July 13, 2026.
See More
Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep Limited, alleging securities fraud by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, highlighting serious governance concerns.
- Trial Discontinuation: On March 13, 2026, Immutep announced the Independent Data Monitoring Committee's recommendation to halt the TACTI-004 Phase III trial, resulting in an 82.44% drop in stock price, indicating significant risks in its research pipeline.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) fell by $2.27 to close at $0.48, reflecting market pessimism regarding the company's future prospects.
- Potential Legal Ramifications: The class action lawsuit could expose Immutep to substantial damages, further impacting its financial health and market credibility, potentially hindering future financing and business development.
See More
Immutep Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has advised Immutep investors of a class action for those who purchased securities between March 24, 2025, and March 12, 2026, with a deadline for lead plaintiff motions set for July 6, 2026, highlighting the urgency of legal action.
- Allegations: The lawsuit claims that Immutep concealed the true status of the TACTI-004 trial regarding the efficacy of efti, despite positive results in other trials, which misled investors and affected their investment decisions.
- Stock Price Plunge: Following the announcement on March 13, 2026, by the Independent Data Monitoring Committee to discontinue the TACTI-004 trial, Immutep's ADRs fell over 82%, reflecting a severe loss of market confidence and investor sentiment.
- Legal Support Offered: The Portnoy Law Firm is providing complimentary case evaluations to assist investors in recovering losses due to corporate misconduct, demonstrating their commitment to protecting investor rights and interests.
See More
